OXURION (EBR:OXUR) | Finanzwire

PRESS RELEASE

published on 05/16/2025 at 08:30, 10 months 9 days ago

Oxurion announces the signing of a binding agreement to acquire French biometrics specialist Axiodis CRO
Oxurion NV to acquire 72% of Axiodis CRO shares for €468,000, valuing the company at €650,000. Deal expected to close by June 2025. Axiodis CRO specializes in clinical biometrics, offers integrated services for clinical trials, and aims for revenue growth

Acquisition Revenue Growth Oxurion NV Axiodis CRO Clinical Biometrics
BRIEF

published on 05/15/2025 at 18:05, 10 months 10 days ago

Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC

Acquisition Actions Transparency Atlas Special Opportunities Oxurion
PRESS RELEASE

published on 05/15/2025 at 18:00, 10 months 10 days ago

Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC
Oxurion announces receipt of transparency notifications regarding share ownership by Atlas Special Opportunities II, LLC, crossing thresholds under and above 5% and 25%

Share Ownership Thresholds Oxurion Atlas Special Opportunities II Transparency Notifications
BRIEF

published on 05/12/2025 at 18:05, 10 months 13 days ago

Oxurion Reports Shares Threshold Crossings by Atlas Special Opportunities

Transparency Notification Atlas Special Opportunities Oxurion Shareholding Thresholds Retinal Disease Therapies
PRESS RELEASE

published on 05/12/2025 at 18:00, 10 months 13 days ago

Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC
Oxurion NV received transparency notifications regarding changes in shareholding percentages from Atlas Special Opportunities II, LLC. The biopharmaceutical company is focused on developing ophthalmic therapies for retinal disease

Biopharmaceutical Shareholding Changes Ophthalmic Therapies Oxurion NV Transparency Notifications
BRIEF

published on 05/09/2025 at 18:05, 10 months 16 days ago

Oxurion Increases Capital Following Convertible Bond Conversion

Convertible Bonds Capital Increase Atlas Special Opportunities Vision Preservation Oxurion Shares
PRESS RELEASE

published on 05/09/2025 at 18:00, 10 months 16 days ago

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
Atlas Special Opportunities, LLC converts 4 convertible bonds in Oxurion, resulting in EUR 100,000 capital increase, supporting innovative therapeutics development for vision preservation in elderly. Oxurion shares update post-capital increase

Capital Increase Oxurion Atlas Special Opportunities, LLC Innovative Therapeutics Vision Preservation
BRIEF

published on 04/25/2025 at 18:35, 11 months ago

Oxurion Stops 2024 Transaction and Continues Negotiations for New Acquisition

Acquisition Negotiations CRO Oxurion Biometrics
PRESS RELEASE

published on 04/25/2025 at 18:30, 11 months ago

Oxurion announces that the transaction of July 2024 is stopped and confirms continuation of discussions regarding the acquisition project announced in March 2025
Oxurion NV halts acquisition of French CRO, pursues deal with biometrics CRO to expand capabilities in clinical data management. Progress updates to follow

Acquisition CRO Oxurion NV Clinical Data Management Biometrics
BRIEF

published on 04/11/2025 at 20:05, 11 months 14 days ago

Oxurion Publishes its 2024 Annual Report and Convenes its General Meeting

Forward-looking Statements Annual Report 2024 Ophthalmic Therapies Shareholders' Meetings Oxurion NV

Published on 03/26/2026 at 00:40, 1 hour 29 minutes ago

Challenger RC Resource Upgrade Drilling Complete
Published on 03/26/2026 at 00:30, 1 hour 39 minutes ago

Nano One Highlights Recent Objectives & Reports Fourth Quarter 2025 Results
Published on 03/25/2026 at 19:15, 6 hours 54 minutes ago

Gemina Laboratories Ltd. Announces Delisting from the CSE
Published on 03/25/2026 at 13:30, 12 hours 39 minutes ago

Prince Silver Files NI 43-101 Technical Report for Its Stampede Gap Porphyry Copper-Gold-Molybdenum Project in Nevada
Published on 03/25/2026 at 13:30, 12 hours 39 minutes ago

Triera Biosciences - a Zentek Company - Launches Contract Research Organization Services for Custom Aptamer Discovery, Biosensor Enablement, and Machine-Learning Classification

View all ACCESSWIRE

Published on 03/26/2026 at 01:05, 1 hour 4 minutes ago

Blokees Announces Upgrade Brand Mission at 2026 Global Partner Conference
Published on 03/25/2026 at 20:00, 6 hours 9 minutes ago

Piramal Pharma Solutions Commemorates 20th Anniversary at Morpeth Facility with Procurement of Korsch X3 Tablet Press
Published on 03/25/2026 at 19:41, 6 hours 28 minutes ago

EQS-Adhoc: STRATEC POSTS IMPAIRMENTS, REPORTS PRELIMINARY RESULTS FOR 2025, AND OFFERS GUIDANCE FOR 2026
Published on 03/25/2026 at 19:30, 6 hours 39 minutes ago

AIXTRON to expand global footprint with new plant in Malaysia
Published on 03/25/2026 at 19:26, 6 hours 43 minutes ago

EQS-Adhoc: AIXTRON SE to expand global footprint with new plant in Malaysia

View all EQS

Published on 03/25/2026 at 18:53, 7 hours 16 minutes ago

LNA SANTE : 2025 Annual Results
Published on 03/25/2026 at 18:31, 7 hours 38 minutes ago

Strong investment performance and active roll-out of our strategy
Published on 03/25/2026 at 17:45, 8 hours 24 minutes ago

Combined General Meeting on May 05, 2026: publication of the notice of Meeting
Published on 03/25/2026 at 17:45, 8 hours 24 minutes ago

GUILLEMOT CORPORATION: 2025 ANNUAL RESULTS
Published on 03/25/2026 at 17:42, 8 hours 27 minutes ago

2025/2026 Second quarter Sales

View all LES ECHOS COMFI WIRE

News